Amid Iran war and AI-driven market jitters, investors could consider these three tech stocks, all rated “Strong Buy” by TipRanks’ Top Analysts. The sector’s momentum continues, driven by breakthroughs in AI, cloud computing, semiconductors, and cybersecurity. For those chasing long-term gains, this high-growth market offers substantial upside. Still, amid lofty valuations and bubble concerns, smart moves demand thorough research and trusted analyst insights.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to Top Wall Street Analysts, each of these stocks recently received a new Buy rating, signaling bullish sentiment. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
Cellebrite DI (CLBT)
Cellebrite DI develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations. Its solutions are used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.
Today, Jonathan Ho, analyst at William Blair reiterated a Buy rating on the stock. Cellebrite is entering a stronger growth phase supported by product innovation and AI integration. He views the company’s platform as increasingly strategic for law enforcement and enterprise customers, reinforced by high customer satisfaction and sizable investments in Cellebrite’s tools relative to competitors.
Over the past three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month average CLBT target is $20.67, which implies an upside of 66%.
Allot (ALLT)
It provides network intelligence and security solutions to protect and personalize the digital experience in Europe, Asia, Oceania, the Middle East, Africa, and the Americas. The company offers Allot Secure Management platform that includes Allot NetworkSecure, Allot HomeSecure, Allot DNSecure, among others.
This week Shaul Eyal, analyst at TD Cowen, reiterated a Buy rating on the stock and set a price target of $11.00. He pointed to accelerating Security-as-a-Service annual recurring revenue, supported by robust cybersecurity demand and the firm’s Security First strategy, which together are driving improved profitability, including the strongest margins the company has delivered in roughly ten years.
Over the past three months, all five Top Analysts covering the stock have given it a Buy rating. Taken together, their 12-month average ALLT target is $13.38, which implies an upside of 87.66%.
Septerna (SEPN)
It is a clinical-stage biotechnology company, which discovers and develops G protein-coupled receptor (GPCR) oral small molecule product candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
This week, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Septerna and set a price target of $40.00. He said the company has advanced SEP-479, an oral PTH1R agonist for hypoparathyroidism, into a sizable Phase 1 trial designed to rigorously assess safety, dosing, and pharmacologic effects, building on robust preclinical data showing strong calcium-regulating activity and good tolerability.
Over the past three months, all five Top Analysts covering the stock have given it a Buy rating. Taken together, their 12-month average SEPN target is $37.27, implying a 55.62% upside.